The global Breast Cancer Market was valued at USD 20.06 billion in 2020 and is expected to reach USD 40.49 billion by the year 2026, at a CAGR of 10.8%.
Major competitors in Breast Cancer Market Includes Pfizer, Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Merck & Co., Bayer AG, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceuticals Industries Ltd, Baxter, Mylan N.V., Fresenius Kabi AG and others.
July 2020- National Cancer Institute Center- There is a new focus on adding targeted therapies to hormone therapy for advanced or metastatic HR-positive breast cancer. These treatments could prolong the time until chemotherapy is needed and ideally, extend survival. Approved drugs include:
- Palbociclib (Ibrance), ribociclib (Kisqali), and everolimus (Afinitor)have all been approved by the FDA recently for use with hormonal therapy for treatment of advanced or metastatic breast cancer.
- Abemaciclib (Verzenio)can be given with hormonal therapy or alone after treatment with hormonal therapy to women with advanced or metastatic ER-positive, HER2-negative breast cancer. These combinations are also being tested to see if they can prevent a relapse after treatment of early-stage ER-positive disease.
- Alpelisib (Piqray)is approved to be used in combination with hormonal therapy to treat HR-positive and HER2-negative breast cancers that have a mutation in the PIK3CA gene.
On Nov. 13, 2020, the U.S. Food and Drug Administration (FDA) approved the immunotherapy Keytruda (chemical name: pembrolizumab) in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.
Sept 2020- Scientists at Johns Hopkins Medicine and the University of Oxford has found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery. The technique, so far tested only on lab-grown and patient-derived cancer cells, could advance efforts to find drugs that kill breast cancer cells in a subset of patients, and leave healthy cells unharmed.
The Pfizer And German Breast Group announced on Oct 2020- that the collaborative Phase-3 of PENELOPE-B trial did not meet the primary endpoint of improve invasive disease-in women which having hormone receptor-positive(HR+) human epidermal growth factor- negative early Breast Cancer who have residual invasive disease after completing neoadjucant chemotherapy.
Eli Lilly and Company announced on Sept 2020 that Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer. This is a major milestone for people living with high risk HR+, HER2- early breast cancer – potentially one of the most notable treatment advances in the last two decades for this population of breast cancer patients.
Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. Basis on treatment type, the breast cancer metastatic market is segmented into chemotherapy, hormone therapy targeted therapy, immunotherapy and others. On the basis of end-users, the breast cancer metastatic market is segmented into hospitals, homecare, specialty clinics and others. By region Analysis it spread in North America, Europe, Asia-Pacific and Row. North America is dominated the market in 2020 due to the advance technology resources and treatment. Also in Europe, Healthcare Expenditure of people is responsible for market growth.
Asia-Pacific represents the fastest growing region in the global breast cancer market. This is due to improving healthcare infrastructure and increasing awareness among people about breast cancer. In developing countries, such as China and India, government has launched several programs and initiatives which increase awareness about the disease.
For more information contact @